Five BCW Index Shops Join Alliance to Curb FDA Plan to Regulate Certain Molecular Dxs | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
More than one-fifth of the companies listed on the BioCommerce Week Index have joined an international coalition that aims to curb plans by the US Food and Drug Administration to regulate certain homebrew diagnostics ordinarily monitored by Clinical Laboratory Improvement Amendments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.